{"chunk_id": "WHO_GUIDELINES(TRAIN DATA)__chunk_611", "source": "WHO_GUIDELINES(TRAIN DATA)", "text": "B.1.2).\n• Stakeholders may wish to consider context-specific ASB screening and treatment based on ASB and \npreterm birth prevalence, as it may not be appropriate in settings with low prevalence.\n• Evidence on preterm birth is of low certainty and large multicentre trials are needed to confirm whether \nscreening and antibiotic treatment reduces preterm birth and perinatal mortality in LMICs. Such trials \nshould also aim to evaluate the effects of group B streptococcus (GBS) screening and treatme"}